Structural Heart Devices Market To Reach $50.99 Billion By 2033

Structural Heart Devices Market Growth & Trends

The global structural heart devices market size is expected to reach USD 50.99 billion by 2033, registering a CAGR of 13.5% from 2025 to 2033, according to a new report by Grand View Research, Inc. The market is expected to witness exponential growth over the next 8 years due to the rapid increase in cardiovascular conditions and increasing power of healthcare expenditure.

The defects are mostly present at birth, thereby directly affecting the under-5 mortality rate of a country. Therefore, rigorous actions are being undertaken by various government bodies across the globe to increase access to treatment. The Centers for Disease Control and Prevention have a public action plan for efficient management of cardiac conditions.

In addition, other organizations are working on improving the scenario for structural heart disease treatment. For instance, in November 2016, the Cardiovascular Research Foundation (CRF) announced a launch of a journal focusing on the diagnosis and treatment of structural heart defects. It was titled Structural Heart: The Journal of the Heart Team and is expected to be launched in May 2017. This is expected to trigger research & development activities along with capital invested in this field, resulting in technological advancements.

 Request a free sample copy or view report summary: Structural Heart Devices Market Report

Structural Heart Devices Market Report Highlights

• Surgical Aortic Valve Replacement (SAVR) dominated the market in 2024, closely followed by Transcatheter Aortic Valve Replacement (TAVR). It can be attributed to the longest presence of the technique in the treatment regimen of aortic stenosis

• Left Atrial Appendage Closure (LAAC) is anticipated to be one of the fastest-growing segment owing to the minimally invasive nature of the procedure. It also helps in the reduction of risk of stroke, thus is projected to have a higher demand

• Geographically, North America dominated the structural heart devices market with a revenue share of 52.5% in 2024,  A high prevalence of cognitive heart diseases is the key reason for this dominance. Moreover, the mandatory CCHD screening for newborns imposed by the Centers for Disease Control and Prevention (CDC) and the American Academy of Pediatrics (AAP) in September 2014 also contributes to the growth in this region

• The Asia Pacific structural heart devices industry is expected to grow fastest over the forecast period. Increasing CVD cases, rising geriatric population, and technological advancement drive the market's growth

Structural Heart Devices Market Segmentation

Grand View Research has segmented the global structural heart devices market report based on type and region:

Structural Heart Devices Type Outlook (Revenue USD Million, 2021 - 2033)

• TAVR (Transcatheter Aortic Valve Replacement)

• SAVR (Surgical Aortic Valve Replacement)

• Mitral Repair (Annuloplasty)

• LAAC (Left Atrial Appendage Closure)

Structural Heart Devices Regional Outlook (Revenue, USD Million, 2021 - 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in Structural Heart Devices Market

• Boston Scientific Corporation

• Medtronic

• Edwards Lifesciences Corporation

• Abbott Laboratories

• ST. JUDE MEDICAL

• Biomerics

• Comed BV

• LivaNova PLC

• JenaValve Technology, Inc.

• CardioKinetix